Intervention Review

Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients

  1. Angela C Webster1,*,
  2. Vincent WS Lee2,
  3. Jeremy R Chapman2,
  4. Jonathan C Craig3

Editorial Group: Cochrane Renal Group

Published Online: 21 JAN 2009

Assessed as up-to-date: 19 FEB 2006

DOI: 10.1002/14651858.CD004290.pub2

Database Title

Additional Information

How to Cite

Webster AC, Lee VWS, Chapman JR, Craig JC. Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients. Cochrane Database of Systematic Reviews 2006, Issue 2. Art. No.: CD004290. DOI: 10.1002/14651858.CD004290.pub2.

Author Information

  1. 1

    University of Sydney, School of Public Health, Sydney, NSW, Australia

  2. 2

    Westmead Hospital, Renal Medicine, Westmead, NSW, Australia

  3. 3

    The Children's Hospital at Westmead, Centre for Kidney Research, Westmead, NSW, Australia

*Angela C Webster, School of Public Health, University of Sydney, Edward Ford Building A27, Sydney, NSW, 2006, Australia. awebster@health.usyd.edu.au. angela.webster@gmail.com.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 21 JAN 2009

SEARCH

ARTICLE TOOLS

View Full Article (HTML) Summary (61K)Standard (607K)Full (2066K)

  1. Current Version

    Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients

    Angela C Webster, Vincent WS Lee, Jeremy R Chapman and Jonathan C Craig

    Article first published online: 21 JAN 2009 | DOI: 10.1002/14651858.CD004290.pub2

Previous versions of this article and their online publication dates

  1. Version 1

    Sirolimus and everolimus for kidney transplant recipients

    AC Webster, G Higgins, JR Chapman and JC Craig

    Article first published online: 25 JAN 2006 | DOI: 10.1002/14651858.CD004290

View Full Article (HTML) Summary (61K)Standard (607K)Full (2066K)